JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

Home・Aandelen Lijst・Smith & Nephew PLC ADR

Search

Smith & Nephew PLC ADR

Gesloten

30.9 -0.9

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

30.72

Max

31.2

Belangrijke statistieken
By Trading Economics
Inkomsten	35M 331M
Verkoop	203M 3.2B
K/W Sectorgemiddelde	22.441 67.147
Dividendrendement	2.44
Winstmarge	10.368
Werknemers	16,988
EBITDA	133M 856M

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	+2.7% upside

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	2.44% 2.36%

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-1.5B 14B
Vorige openingsprijs	31.8
Vorige sluitingsprijs	30.9

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

26.64 / 28.37 Steun & Weerstand

Smith & Nephew PLC ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 mei 2026, 22:17 UTC

Winsten

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4 mei 2026, 23:47 UTC

Winsten

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4 mei 2026, 23:45 UTC

Winsten

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4 mei 2026, 23:45 UTC

Winsten

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4 mei 2026, 23:40 UTC

Marktinformatie

Gold Steady Amid Likely Technical Recovery -- Market Talk

4 mei 2026, 22:44 UTC

Acquisities, Fusies, Overnames

Regis: Jim Beyer To Be Chief Executive of Combined Company

4 mei 2026, 22:43 UTC

Acquisities, Fusies, Overnames

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4 mei 2026, 22:42 UTC

Acquisities, Fusies, Overnames

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4 mei 2026, 22:42 UTC

Acquisities, Fusies, Overnames

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4 mei 2026, 22:41 UTC

Acquisities, Fusies, Overnames

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4 mei 2026, 22:41 UTC

Acquisities, Fusies, Overnames

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4 mei 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Regis: Shareholders to Own About 51% of Combined Company

4 mei 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Regis: Board Unanimously Endorsed, Supported Deal

4 mei 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Regis: Deal Unanimously Recommended by Vault Board

4 mei 2026, 22:39 UTC

Acquisities, Fusies, Overnames

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4 mei 2026, 22:38 UTC

Acquisities, Fusies, Overnames

Regis Resources to Acquire All Ordinary Shares in Vault

4 mei 2026, 22:38 UTC

Acquisities, Fusies, Overnames

Regis Resources, Vault Minerals Agree to Merger of Equals

4 mei 2026, 22:37 UTC

Winsten

Acquisities, Fusies, Overnames

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4 mei 2026, 22:26 UTC

Winsten

Acquisities, Fusies, Overnames

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4 mei 2026, 22:02 UTC

Winsten

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4 mei 2026, 22:00 UTC

Marktinformatie

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4 mei 2026, 21:52 UTC

Winsten

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4 mei 2026, 21:50 UTC

Winsten

Westpac: Some Sectors More Affected Than Others>WBC.AU

4 mei 2026, 21:50 UTC

Winsten

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4 mei 2026, 21:49 UTC

Winsten

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4 mei 2026, 21:44 UTC

Winsten

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4 mei 2026, 21:44 UTC

Winsten

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4 mei 2026, 21:43 UTC

Winsten

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4 mei 2026, 21:41 UTC

Winsten

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4 mei 2026, 21:40 UTC

Winsten

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Peer Vergelijking

Prijswijziging

Smith & Nephew PLC ADR Prognose

Koersdoel

By TipRanks

2.7% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 32 USD 2.7%

Hoogste 32 USD

Laagste 32 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Smith & Nephew PLC ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

1 ratings

0

Buy

1

Hold

0

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan Smith & Nephew PLC ADR - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

26.64 / 28.37Steun & Weerstand

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Andere aandelen uit de sector

JNJ

Johnson and Johnson

224.16

UNH

UnitedHealth Group Inc

370.76

TMO

Thermo Fisher Scientific Inc

462.35

ISRG

Intuitive Surgical Inc

452.39

ABT

Abbott Laboratories

87.56

Live chat